Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.

Under the agreement, Lilly will manufacture the drug and Cipla will market it under the brand name Yurpeak, the drugmakers said.

Yurpeak to launch once-weekly pre-filled injector pen

Yurpeak will be available as a once-weekly pre-filled injector pen, same as Lilly’s Mounjaro Kwikpen, allowing healthcare providers to personalise treatment plans to individual patient needs.

The medication will be available in six dose strengths – 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg and will be priced the same as Mounjaro.

Lilly’s Mounjaro sales double within months of India launch

Lilly began selling Mo

See Full Page